These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 8595509)

  • 1. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACTG 175 and Delta.
    Torres G
    GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZT studies reinforce benefits of combination.
    AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZT delta study: major European/Australian study finds combinations better than AZT alone.
    King E
    AIDS Treat News; 1995 Oct; (no 232):3-4. PubMed ID: 11362876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
    Whitfield RM; Bechtel LM; Starich GH
    Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of two studies: Delta I/II and ACTG 175].
    Biehler GV
    Sidahora; 1996 Dec-1997 Jan; ():37-40. PubMed ID: 11363441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral drug resistance.
    Japour AJ
    AIDS Clin Care; 1995 Aug; 7(8):63-5, 67. PubMed ID: 11362787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Back to the nukes.
    Smart T
    GMHC Treat Issues; 1996 Feb; 10(2):6-7. PubMed ID: 11363383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HIV infection--current possibilities in antiviral therapy].
    Hirschel B
    Ther Umsch; 1994 Aug; 51(8):545-50. PubMed ID: 7940411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies confirm value of early and combination treatments.
    Vazquez E
    Posit Aware; 1995; VI(6):8. PubMed ID: 11363148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Researchers are rethinking role of AZT in drug therapy.
    AIDS Policy Law; 1995 Oct; 10(18):11. PubMed ID: 11362821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
    Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
    Cochrane Database Syst Rev; 2000; (3):CD002038. PubMed ID: 10908523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What we know about anti-HIV drugs.
    Treat Rev; 1995 May; (no 18):3-4. PubMed ID: 11362592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
    AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival effects of ZDV, ddI, and ddC in patients with CD4 < or = 50 cells/mm3.
    Kazempour K; Kammerman LA; Farr SS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S97-106. PubMed ID: 7552521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3TC approval may revive AZT's appeal.
    Vazquez E
    Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of combination therapy confirmed.
    Cheng B
    PI Perspect; 1995 Dec; (no 17):3-4. PubMed ID: 11363111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.